Quick Answer
ALX ONCOLOGY HOLDINGS INC reported Total Assets of $59.05 million for the year ending 2025.
- ALX ONCOLOGY HOLDINGS INC showed a decrease of -60.0% in Total Assets from 2024 to 2025.
- This data is from ALX ONCOLOGY HOLDINGS INC's annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $103.11 million | Q3 2020: $262.45 million | Q1 2021: $432.91 million | Q2 2021: $421.29 million | Q3 2021: $399.73 million | Q1 2022: $363.68 million | Q2 2022: $346.02 million | Q3 2022: $317.69 million | Q1 2023: $278.14 million | Q2 2023: $245.93 million | Q3 2023: $220.11 million | Q1 2024: $212.65 million | Q2 2024: $214.62 million | Q3 2024: $185.72 million | Q1 2025: $120.90 million | Q2 2025: $95.32 million | Q3 2025: $82.72 million.
- Over the full 7 years of available data (2019 to 2025), ALX ONCOLOGY HOLDINGS INC's Total Assets has grown by 453.1%.
- Historical annual values: Fiscal year 2025: $59.05 million | Fiscal year 2024: $147.78 million | Fiscal year 2023: $242.55 million | Fiscal year 2022: $306.49 million | Fiscal year 2021: $380.18 million | Fiscal year 2020: $436.05 million | Fiscal year 2019: $10.68 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: